Sitagliptin Phosphate CAS No: 654671-78-0 Sitagliptin Phosphate was approved more than a decade ago primarily as a way to combat type 2 diabetes. This dipeptidyl-peptidase-4 inhibitor lowers the levels of glucose in the patient directly following a meal and can also help regulate general blood sugar levels over time. It’s usually used in combination with[…]
Sitagliptin Phosphate: A Blockbuster DPP-4 Inhibitor for Treating Type-2 Diabetes
Anti-Diabetic, Drug Research & Development API Tags: diabetes Jul 11, 2018
Insulin Glargine gives New Hope for those with Type-2 Diabetes in New Clinical Trials
Anti-Diabetic, Drug Research & Development API, Patent Expiration 2023 Tags: anti-diabetic Dec 31, 2015
New Clinical Trials on Insulin Glargine gives New Hope for those with Type-2 Diabetes
Saxagliptin Hydrochloride- The Most Efficient Substitute for Insulin
Anti-Diabetic, Drug Research & Development API, Gliptin, Patent Expiration 2023 Tags: Saxagliptin Dec 15, 2015
The Hyderabad-based pharmaceutical company, Lee Pharma, has recently released a statement which says that Saxagliptin hydrochloride is the most effective substitute for insulin injectables for the treatment of Type-2 diabetes. The statement was made while Lee Pharma said that the multinational company AstraZeneca, which it applied to for the patented diabetes medication Saxagliptin hydrochloride, was[…]
Linagliptin Could be the Answer to Macrovascular Complications Type-2 Diabetics
Anti-Diabetic, Blood Glucose Regulator, Drug Research & Development API, Gliptin Tags: anti-diabeticLinagliptin Dec 01, 2015
A new study reveals that patients diagnosed with Type2-diabetes are at an increased risk of developing macrovascular and microvascular complications. Researchers are currently using a drug called Linagliptin which is an anti-diabetic drug that works by increasing the levels of incretins to help control blood sugar levels, especially after meals. According to reports, the cardiovascular[…]
Exenatide Capsule Gleans Patent in Israel
Anti-Diabetic, Blood Glucose Regulator, Drug Research & Development API, OTC and Compounding Product, Synthetic Peptide Tags: United States Jun 17, 2015
Known as the brand name Byetta in the United States, which is marketed by AstraZeneca, Exenatide is a GLP-1 analog that is currently offered as an injectable treatment for type 2 diabetes. In mid-January 2015 Oramed Pharmaceuticals was granted a patent in Israel for the oral administration of Exenatide. As an effectual therapy for patients[…]
Canagliflozin Continues to be a Viable Treatment for Type 2 Diabetes
Anti-Diabetic, Drug Research & Development API Tags: canagliflozinHbA1c Apr 06, 2015
On January 16, 2015 the Journal of Diabetes and its Complications shared positive findings from a recent post hoc analysis of Canagliflozin. Comprehensive data was analyzed from Phase 3 studies of Canagliflozin in adult patients with type 2 diabetes. This placebo-controlled study was comprised of four 26 week periods, with changes in HbA1c being sought[…]
Can Dapagliflozin and Canagliflozin Fight Type 2 Diabetes and Obesity?
Anti-Diabetic, Drug Research & Development API Tags: DapagliflozinEuropeObesityUnited States Mar 03, 2015
An article published in January 2015 in Diabetes, Obesity and Metabolism explored the pharmacodynamics and the benefits of Dapagliflozin and Canagliflozin in the fight against obesity and type 2 diabetes. This double-blind, randomized study involved both males and females between the ages of 18 and 55. All participants were deemed healthy and free of significant[…]
Liraglutide FDA Approval Brings First Ever Injectable Weight Loss Drug
Anti-Diabetic, Anti-Obesity Product, FDA Approved 2014 Tags: LiraglutideUnited States Jan 26, 2015
The close of 2014 brought exciting news for Novo Nordisk’s innovative weight loss drug Saxenda. The Liraglutide FDA approval is the first of its kind as it’s the only available injectable treatment for obesity. The FDA overwhelmingly gave a nod to this easy to use form of Liraglutide as a safe and effectual option for[…]
Xigduo FDA Approved for Once Daily Type 2 Diabetes Treatment
Anti-Diabetic, Blood Glucose Regulator, FDA Approved 2014, OTC and Compounding Product Tags: Australiatype 2 Diabetes Nov 03, 2014
British-Swedish drugmaker AstraZeneca has been approved by the FDA for its once-a-day Xigduo XR extended-release tablet to treat adults with type 2 diabetes mellitus in the United States. AstraZeneca’s once-daily tablet is indicated as an adjunct therapy to diet and exercise to improve glycaemic control. Xigduo XR is already approved in Australia, and Xigduo is[…]
Dapagliflozin and Saxagliptin Make a Dazzling Duo
Anti-Diabetic, Drug Research & Development API Tags: DapagliflozinHbA1cSaxagliptintype 2 diabetes mellitus May 23, 2014
The latest news in the fight against type 2 diabetes highlights Dapagliflozin and Saxagliptin as the latest dazzling duo. Known as the brand name medications Farxiga {Dapagliflozin} and Onglyza {Saxagliptin} these powerhouse drugs have proven themselves in Phase lll trials. Data recently released from the 534 patient, three-arm trial demonstrated that the combination treatment of[…]
